Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70094 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Keisuke Nosaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmacy, Hyogo Medical University, Kobe, Japan. Hauptthemen laut MEDLINE: Ranibizumab, Recombinant Fusion Proteins, Angiogenesis Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study aimed to identify the potential associations between intravitreal administration of anti‐vascular endothelial growth factor (anti‐VEGF) monoclonal antibodies (ranibizumab, aflibercept, and brolucizumab) and cardiovascular or cerebrovascular adverse events using the Japanese Adverse Drug Event Reporting (JADER) database. We conducted a disproportionality analysis using the JADER database from April 2004 to December 2024 to evaluate the cardiovascular and cerebrovascular adverse events associated with intravitreal administration of ranibizumab, aflibercept, and brolucizumab. Time‐to‐onset distribution and post‐onset outcomes were also analyzed. Disproportional signals were observed for cerebral and myocardial infarction associated with ranibizumab and aflibercept, but not with brolucizumab. Time‐to‐onset analysis showed earlier onset patterns for ranibizumab than for aflibercept, with Weibull shape parameters indicating an early failure‐type distribution. Post‐event outcome analysis revealed some events resulting in sequelae or death, although many reports had unknown outcomes. This study identified the potential cardiovascular and cerebrovascular safety signals associated with intravitreal administration of ranibizumab and aflibercept. Although brolucizumab showed no significant disproportionality, interpretation requires caution because of limited data. Our findings underscore the importance of continued pharmacovigilance and hypothesis‐driven investigations to ensure the safe use of anti‐VEGF therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmacy, Hyogo Medical University, Kobe, Japan.
- Department of Pharmacy, NHO Higashi-Ohmi General Medical Center, Higashi-Ohmi, Shiga, Japan.
- Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan.
- Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
Zitieren
APA
Nosaka, K., Nagano, S., Fujiwara, M., Yamaoka, K., Uesawa, Y., Uchida, M., & Shimizu, T. (2026). Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70094
Vancouver
Nosaka K, Nagano S, Fujiwara M, Yamaoka K, Uesawa Y, Uchida M, et al. Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70094
BibTeX
@article{Nosaka2026,
author = {Nosaka, Keisuke and Nagano, Shuji and Fujiwara, Masaki and Yamaoka, Kenta and Uesawa, Yoshihiro and Uchida, Mayako and Shimizu, Tadashi},
title = {Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70094}
}
EUVIMED